Helei Hou
Overview
Explore the profile of Helei Hou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
836
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lan H, Zhu J, Hou H, Zhang C, Huo X, Zhang Y, et al.
Cell Commun Signal
. 2025 Mar;
23(1):137.
PMID: 40087780
Purpose: Limited treatment options exist for refractory ovarian cancer (OC) due to its poor response to immune therapies. Therefore, there is an urgent need to develop new effective treatment strategies....
2.
Sun D, Hou H, Feng F, Wu W, Tan J, Xie T, et al.
Exp Hematol Oncol
. 2025 Jan;
14(1):3.
PMID: 39773749
Background: Osimertinib has emerged as a critical element in the treatment landscape following recent clinical trials. Further investigation into the mechanisms driving resistance to Osimertinib is necessary to address the...
3.
Xu M, Huo X, Zhang C, Zhang X, Wang H, Yang H, et al.
Hum Vaccin Immunother
. 2024 Nov;
20(1):2431384.
PMID: 39610029
This case study details an innovative conversion therapy strategy in a 58-year-old Asian male with baseline stage cTNM advanced lung squamous cell carcinoma (SCC) harboring a rare exon 20 insertion...
4.
Zhang Y, Hou H, Zhang X, Lan H, Huo X, Duan X, et al.
Dig Dis Sci
. 2024 Nov;
70(1):262-284.
PMID: 39604668
Background: Because of the unique tumor microenvironment (TME), immunotherapy and targeted therapies have shown limited efficacy in treating pancreatic adenocarcinoma (PAAD). CD8 + T cells play crucial roles in regulating...
5.
Zhang X, Wang H, Li Y, Yan W, Chen Y, Song S, et al.
World J Surg Oncol
. 2024 Nov;
22(1):313.
PMID: 39593126
Background: Currently, PD-(L)1 blockade-based neoadjuvant treatment has shown promising outcomes in patients with potentially resectable gastric cancer. In this real-world study, we aimed to retrospectively observe the efficacy including tumor...
6.
Zhang Y, Sun D, Han W, Yang Z, Lu Y, Zhang X, et al.
FEBS Open Bio
. 2024 Sep;
14(12):2086-2103.
PMID: 39322625
The switch/sucrose non-fermenting (SWI/SNF) complex family includes important chromatin-remodeling factors that are frequently mutated in lung adenocarcinoma (LUAD). However, the role of one family member, SMARCA4, in LUAD prognosis and...
7.
Huo X, Han W, Yang Z, Lu Y, Liu N, Hou H
J Gene Med
. 2024 Aug;
26(8):e3729.
PMID: 39146560
Identifying biomarkers to predict immune checkpoint inhibitor (ICI) efficacy is warranted. Considering that somatic mutation-derived neoantigens induce strong immune responses, patients with a high tumor mutational burden reportedly tend to...
8.
Zhang X, Zhang H, Hou F, Fang T, Zhang C, Wang H, et al.
World J Surg Oncol
. 2024 Jun;
22(1):159.
PMID: 38890622
Background: Whether programmed cell death-1/ligand-1 (PD-1/PD-L1) blockade-based neoadjuvant treatment may benefit locally advanced oncogene-mutant non-small cell lung cancer (NSCLC) patients remains controversial. This retrospective study was designed to observe the...
9.
Zhou H, Sun D, Song S, Niu Y, Zhang Y, Lan H, et al.
Discov Oncol
. 2024 Jun;
15(1):213.
PMID: 38847966
Background: Immune checkpoint inhibitors (ICIs), especially those targeting programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1), have introduced a new treatment landscape for many types of tumors. However,...
10.
Zhang C, Wang G, Liu N, Li T, Zhu J, Hou H
Front Immunol
. 2024 Apr;
15:1387465.
PMID: 38646529
Background: Camrelizumab, a programmed death 1 (PD-1) inhibiting antibody, has demonstrated efficacy in various malignancies and received approval in multiple countries. Despite its therapeutic benefits, camrelizumab is associated with a...